Introduction
============

Medulloblastoma (MB), a neuroepithelial tumor developing in the cerebellum, is the most common pediatric brain cancer and represents about 20% of all cerebral childhood tumors ([@B20]; [@B15]). The current therapy of MB involves preliminary surgery, radiation, and chemotherapy. This standard multimodality treatment allows acceptable survival rates, but patients suffer devastating morbidity, such as permanent neurocognitive dysfunctions ([@B9]) and secondary malignancies ([@B8]). Thus, new, less toxic and more targeted, therapy options are needed.

About 30% of MBs originate from the granule neuron precursor cells (GCPs) located in the external granular layer (EGL) at the surface of the developing cerebellum, in consequence of the proliferative hyperactivation of the Sonic Hedgehog (Shh) pathway ([@B22]; [@B27]; [@B7]; [@B17]). In physiological conditions, the GCPs intensely proliferate postnatally in the EGL mitogenic niche, under the stimulus of Shh, and exit the cell cycle and differentiate as a result of migrating inward to molecular and internal granular layers (ML and IGL, respectively) ([@B2]). Given that the prolonged mitotic activity makes the GCPs especially susceptible to cell transformation ([@B25]), the rate of migration, by regulating the duration of the period during which GCPs remain proliferating in the EGL, can impact the incidence of MBs, as we and others have shown ([@B3], [@B4]; [@B10]). In fact, our recent study demonstrated that a new MB Shh-type mouse model, which lacks the MB-suppressor gene *Tis21* (*Ptch1*^+/-^/*Tis21*^-/-^), develops MBs with high frequency in consequence of a defect of migration of the GCPs out of the EGL ([@B5], [@B3]). This defect of migration is caused by downregulation of the chemokine Cxcl3, whose promoter is directly activated by Tis21 ([@B3]). We also revealed the ability of the chemokine Cxcl3 to cell autonomously induce the migration of the GCPs out of the EGL and, remarkably, to reduce the area of MB lesions in cerebellar slices of the MB *Ptch1*^+/-^/*Tis21*^-/-^ mouse model ([@B3]).

It is known that the preneoplastic GCPs (pGCPs) within MB lesions, although they are able to generate a tumor when transplanted, can still migrate and differentiate like normal GCPs ([@B27]; [@B12]). Thus, we reasoned that if pGCPs are induced to migrate out of the lesion at the surface of the cerebellum, they may differentiate and exit the neoplastic program.

Therefore, the chief aim of this study was to assess the feasibility of using *in vivo* the pro-migratory chemokine Cxcl3 as an agent able to reduce the frequency of tumor lesions and, hence, to contrast the development of MB.

Materials and Methods {#s1}
=====================

Mice
----

The *Tis21* knockout mice were previously generated in the C57BL/6 strain as described ([@B18]), by inserting the neomycin resistance cassette within exon II of the *Tis21* gene. *Patched1* heterozygous mice (*Ptch1*^+/-^) were produced in CD1 background through deletion of exons 6 and 7 ([@B11]). The crossing of *Ptch1*^+/-^ with *Tis21*^-/-^ mice generated *Ptch1*^+/-^/*Tis21*^-/-^ double-mutant mice, which were interbred for at least six generations to obtain an isogenic progeny.

Genotyping of *Ptch1*^+/-^/*Tis21*^-/-^ mice was routinely performed by PCR analysis, using genomic DNA from tail tips as described ([@B3]).

Experiments were performed with either male or female mice and all animal procedures were accomplished according to the current European Ethical Committee guidelines (directive 2010/63/EU; authorization DM 307/2013-B of the Italian Ministry of Health).

Brain Infusion
--------------

All mice involved in our study (*n* = 30) were anesthetized (80/80/10 mg/kg tiletamine HCl/zolazepam HCl/xylazine, i.p.) and implanted with an Alzet osmotic minipump at postnatal day 30 (P30), as described ([@B14]). Briefly, an Alzet 30-g infusion cannula (length 1.5 mm; brain infusion kit 3; Durect Corp., Cupertino, CA, USA) was implanted into the subarachnoid space above the rostral, dorsal cerebellum, 4 mm caudal to lambda at midline. The Alzet minipump (1004, which delivers 0.11 μl/h for 4 weeks; Durect Corp.) was filled with recombinant Cxcl3 (100 μl of a solution at 20 μg/ml; 5568-CA-025/CF, R&D Systems, Minneapolis, MN, USA) or with the vehicle (CSF, cerebrospinal fluid solution, as per Durect Corp. protocol: 148 mM NaCl, 3 mM KCl, 1.4 mM CaCl~2~, 0.8 mM MgCl~2~, 8 mM Na~2~HPO~4~, 0.2 mM NaH~2~PO~4~) and placed between the scapulas. The cannula was secured with cyanoacrylate and the skin was closed with sutures. An intraperitoneal injection of 0.9% normal saline was given after surgery to prevent post-operative dehydration. Animals were monitored post-operatively until mobile, and they were observed daily until the end of treatment (2 or 4 weeks). The number of mice for each experimental group is summarized in **Table [1](#T1){ref-type="table"}**.

###### 

Frequency of medulloblastoma lesions after Cxcl3 treatment.

  Treatment                                               Mice with MB lesions (%, \#)   Number of MB lesions per cerebellum^∗^ (Mean ± SEM)                
  ------------------------------------------------------- ------------------------------ ----------------------------------------------------- ------------ ------------
  28 days in 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice   CSF                            Cxcl3                                                 CSF          Cxcl3
                                                          62.5 (5/8)                     0.00 (0/8)                                            0.62 ± 0.1   0.0 ± 0.0
  n (mice) analyzed                                       8                              8                                                     8            8
  Probability (*p*)                                       0.007 (Chi square test)        0.0042 (Student's *t-*test)                                        
                                                                                                                                                            
  14 days in 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice   CSF                            Cxcl3                                                 CSF          Cxcl3
                                                          42.8 (3/7)                     28.5 (2/7)                                            0.42 ± 0.2   0.28 ± 0.1
  n (mice) analyzed                                       7                              7                                                     7            7
  Probability (*p*)                                       0.57 (Chi square test)         0.61 (Student's *t-*test)                                          

∗

Average number in lesioned and non-lesioned mice.

Bromodeoxyuridine Treatment of Mice
-----------------------------------

The pGCPs entering S-phase were detected 1 h after an injection of bromodeoxyuridine (BrdU) (95 mg/kg, i.p.), according to existing protocols ([@B1]; [@B19]).

The pGCPs migrating from the lesions to the inner layers were visualized 5 days after a single injection of BrdU (95 mg/kg, i.p.) in P39 mice.

Immunohistochemistry
--------------------

At the end of treatment, the mice were euthanized under anesthesia by transcardiac perfusion with 4% paraformaldehyde in PBS and the cerebella were dissected and cryoprotected in 30% sucrose in PBS. Samples were embedded in Tissue-Tek OCT (Sakura Finetek, Torrance, CA, USA) and free-floating sagittal sections of 40 μm were cut serially on a rotary microtome. To detect the BrdU incorporation, the sections were treated with 2N HCl 45 min at 37°C and then with 0.1 M sodium borate buffer, pH 8.5, for 10 min. The samples were reacted with a rat monoclonal antibody against BrdU (AbD Serotec, Raleigh, NC, USA; MCA2060; 1:300) and a mouse monoclonal antibody raised against NeuN (Merck Millipore, Billerica, MA, USA; MAB377; 1:100), followed by donkey anti-rat tetramethylrhodamine isothiocyanate (TRITC)-conjugated and donkey anti-mouse Cy2-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA; 1:200). The samples were then counter-stained by Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA; 1 mg/ml in PBS) to visualize the ML and IGL.

Photomicrographs of the immunostained sections were generated by Laser Scanning Confocal Microscopy with a TCS SP5 microscope (Leica Microsystems) and analyzed by the I.A.S. software (Delta Sistemi, Rome, Italy).

Lesion Quantification and Cell Migration Assay
----------------------------------------------

All cerebella were stained for BrdU incorporation using fluorescent methods, as described above, to identify the presence of lesions. For each cerebellum were examined 12 sections spaced with intervals of 400 μm, in order to allow a representative sampling.

The pGCPs migrating from the lesions were identified as BrdU-labeled cells in MB lesion and neighboring layers (i.e., ML and IGL) and were counted as percentage ratio to the total number of BrdU^+^ cells in the lesion and layers, in 10 adjacent sagittal sections per lesion. We examined all lesions present in each 6-week-old mouse analyzed, whose number for each treatment is indicated in **Table [1](#T1){ref-type="table"}**.

Statistical Analysis
--------------------

The Chi square test was used to compare the percentage of positivity for MB lesions in CSF-treated mice versus Cxcl3-treated mice. Data of migration and differentiation of pGCPs were calculated as the mean ± the standard error of the mean (SEM) and compared by the Student's *t*-test. All statistical tests were two-sided and a value of *p* \< 0.05 was considered statistically significant.

Results
=======

The chemokine Cxcl3 or the vehicle (CSF) was administered by Alzet osmotic minipumps in the cerebella of the *Ptch1*^+/-^/*Tis21*^-/-^ mice, a mouse model that we have previously generated, which develops Shh-dependent MBs at high frequency (80%) ([@B3]). The treatment lasted 4 weeks and started in 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice, i.e., at a stage when MB lesions, generated by pGCPs, have already started to form and represent MB at its initial expansion ([@B13]; [@B3]). The lesions were identified by visualizing the proliferating pGCPs as BrdU^+^ cells, 1 h after an injection of BrdU (**Figures [1A,B](#F1){ref-type="fig"}**). As shown in **Figures [1C--E](#F1){ref-type="fig"}** and in **Table [1](#T1){ref-type="table"}**, we observed that in 2-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice, previously treated with Cxcl3 for 28 days, the percentage of mice presenting cerebellar lesions was 0.0%, whereas it was 62.5% in CSF-treated mice (*p* = 0.007 Chi square test; *n* = 8 mice treated with Cxcl3 and *n* = 8 mice treated with CSF). Correspondingly, the average number of MB lesions per cerebellum resulted 0.0 ± 0.0 in Cxcl3-treated and 0.62 ± 0.1 in vehicle-treated mice (*p* = 0.0042 Student's *t*-test). Thus, the chronic infusion of the chemokine Cxcl3 into the cerebellum of the high frequency MB mouse model *Ptch1*^+/-^/*Tis21*^-/-^ prevents and/or suppresses the development of MB lesions.

![**Administration of Cxcl3 for 28 days suppresses the development of MB lesions. (A)** Scheme of minipump implant and **(B)** treatment timeline: 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice were treated for 4 weeks with Alzet minipumps filled with recombinant Cxcl3 or with CSF alone; a single BrdU injection was performed 1 h before analysis. **(C,D)** Representative images of cerebellar sagittal sections from 2-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice treated with CSF **(C)** or Cxcl3 **(D)**, with or without an MB lesion, respectively. Nuclei were stained with Hoechst 33258 and lesions were identified by the presence of BrdU^+^ pGCPs (red). Scale bar, 300 μm. **(E)** Higher magnification of the preneoplastic lesion indicated in **(C)** (white box). Scale bar, 100 μm.](fphar-07-00484-g001){#F1}

As a next step, we sought to define whether this striking anti-lesion effect was dependent on the duration of Cxcl3 application. We analyzed the frequency of MB lesions by treating 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice for a shorter period (14 days) with the same Alzet minipumps filled with recombinant Cxcl3 or with CSF (**Figure [2A](#F2){ref-type="fig"}**). At this time no significant differences were detected between Cxcl3-treated and CSF-treated mice in the percentage of MB lesions or in the number of lesions per cerebellum (see **Table [1](#T1){ref-type="table"}**), indicating that 2 weeks of Cxcl3 treatment are not sufficient to counteract the development of the MB lesions.

![**Cxcl3 delivered *in vivo* in the cerebellum has a strong pro-migratory effect on pGCPs. (A)** Scheme of treatment: 1-month-old *Ptch1*^+/-^/*Tis21*^-/-^ mice were treated for 14 days with Alzet minipumps filled with recombinant Cxcl3 or with CSF alone; mice received a single BrdU injection at P39 and were analyzed 5 days after (P44). **(B)** Representative confocal images of pGCPs migrating outside the lesions, identified at 6 weeks of age as BrdU^+^ cells (red) in the *Ptch1*^+/-^/*Tis21*^-/-^ mice treated with CSF or Cxcl3. Sections are counterstained with Hoechst 33258 to visualize the ML and the IGL. Scale bar, 50 μm. L: lesion. **(C)** The pGCPs migrating from lesions were quantified as mean ± SEM percentage ratio of BrdU^+^ cells present within the ML or the IGL area neighboring each lesion to the total number of BrdU^+^ cells in lesion, ML and IGL. All lesions present in each mouse cerebellum were analyzed. CSF *n* = 3 lesions (seven mice), Cxcl3 *n* = 2 lesions (seven mice). ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, Student's *t*-test. **(D)** The same confocal sections of **(B)** are shown with pGCPs double labeled for BrdU^+^NeuN^+^ (red and green, respectively) and counterstained with Hoechst 33258 to visualize the ML and the IGL. Scale bar, 50 μm. White arrows indicate some of the BrdU^+^NeuN^+^ cells. **(E)** Quantification of the differentiated pGCPs \[shown in graph **(C)** as BrdU^+^\], analyzed as mean ± SEM percentage ratio of BrdU^+^NeuN^+^ cells present within the ML or the IGL area neighboring each lesion to the total number of BrdU^+^ cells in lesion, ML and IGL. CSF *n* = 3 lesions (seven mice), Cxcl3 *n* = 2 lesions (seven mice). ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, Student's *t*-test.](fphar-07-00484-g002){#F2}

Thus, we reasoned that the absence of lesions in mice treated for a month with Cxcl3 could depend on the protracted period of forced migration out of the lesion of the pGCPs induced by the chemokine. Then, to verify the effect of Cxcl3 on pGCPs migration and differentiation, we analyzed the percentage of pGCPs migrated outside lesions in 6-week-old *Ptch1*^+/-^/*Tis21*^-/-^ mice previously treated with Cxcl3 or CSF for 14 days, labeled with one injection of BrdU 5 days before analysis, and following their migration to the ML and IGL (**Figures [2A--C](#F2){ref-type="fig"}**). pGCPs were double labeled (BrdU^+^NeuN^+^) to monitor also their differentiation (**Figures [2D,E](#F2){ref-type="fig"}**); in fact NeuN marks post-mitotic, terminally differentiated, cerebellar granule neurons ([@B26]). In Cxcl3-treated mice we observed an evident increase in the percentage of BrdU^+^ pGCPs migrated from the lesion to the ML and IGL (about 80% and fourfold, respectively), relative to control mice (percentage of BrdU^+^/total BrdU^+^ in Cxcl3-treated vs. CSF-treated mice, *p* = 0.0013 in ML and *p* = 0.00008 in IGL; **Figures [2B,C](#F2){ref-type="fig"}**). Almost all of the BrdU^+^ pGCPs migrated to the ML and IGL resulted terminally differentiated (85 and 90%, respectively; percentage of BrdU^+^NeuN^+^/total BrdU^+^ cells in Cxcl3-treated vs. CSF-treated mice, *p* = 0.002 in ML and *p* = 0.00008 in IGL; **Figures [2D,E](#F2){ref-type="fig"}**).

We conclude that Cxcl3 delivered *in vivo* in the cerebellum exerts a powerful pro-migratory effect on pGCPs -- continuously forcing them to leave lesions -- accompanied by a pro-differentiative effect resulting from the exit of pGCPs out of the mitogenic area at the cerebellar surface.

Discussion
==========

Current cancer therapies target proliferation and survival of tumor cells, mainly using toxic chemicals. Instead, in this study we tested the feasibility to reduce the frequency of MB lesions by forcing the preneoplastic granule neuron precursor cells (pGCPs) to migrate out of the lesions at the surface of the cerebellum and differentiate, withdrawing from the tumor program, by means of an intracerebellar treatment with the chemokine Cxcl3.

Some chemokines have been shown to be expressed in cerebellum, such as Cxcl2 ([@B21]), or Cxcl12 and Cxcl3, which inhibit ([@B16]) or promote ([@B3]), respectively, the migration of the GCPs out of the EGL.

Moreover, we have recently shown by real time-PCR and by *in situ* analysis that the chemokine Cxcl3 is expressed in normal as well as in preneoplastic GCPs in MB lesions and also in granule neurons in the IGL; furthermore, we have ascertained the expression of the Cxcl3 receptor (CXCR2) in GCPs ([@B3]).

To increase the levels of Cxcl3 *in vivo* in the pGCPs of the high frequency MB mouse model *Ptch1*^+/-^/*Tis21*^-/-^, we treated chronically 1-month-old mice with Cxcl3 in cerebellum by implantation of Alzet osmotic minipumps. As a result, after 1 month of intracerebellar administration of the chemokine, the tumor lesions disappeared or were prevented completely. Since the tumor lesions present at 2 months of age in *Ptch1*^+/-^/*Tis21*^-/-^ mice develop invariably into a MB ([@B3]), these data represent a proof of concept that the treatment with Cxcl3 can reduce MB formation. This suggests that the timing chosen to start the treatment, i.e., when the lesions have already started to develop (1 month after birth), is appropriate. Nevertheless, since a shorter treatment does not attain a significant reduction of lesion number, this study also suggests that the reduction of the frequency of MB lesions is dependent on the duration of Cxcl3 application. The observed delay in Cxcl3 effect on lesion frequency after 14 days of treatment may depend on the time required for diffusion and influence of Cxcl3 on brain microenvironment. In fact, in isolated cerebellar slices from MB *Ptch1*^+/-^/*Tis21*^-/-^ mice we observed a rapid decrease of the area of MB lesions within 5 days ([@B3]).

Notably, we showed in this report that the absence of lesions in the mice treated with Cxcl3 was correlated with increased migration out of the lesion and with differentiation of the pGCPs following the exposure to the chemokine. In fact, in mice treated with Cxcl3 for 2 weeks we observed a significant increase in the percentage of differentiated pGCPs (BrdU^+^NeuN^+^) migrated out of the lesion to the ML and IGL, relative to control mice. Interestingly, the percentage of BrdU^+^ pGCPs migrated out the lesion to either the ML or IGL of CSF-treated *Ptch1*^+/-^/*Tis21*^-/-^ mice matched the values of the pGCPs migration previously observed without minipumps ([@B3]), thus ruling out a possible effect of the CSF treatment on the ability of pGCPs to migrate out of lesions.

As a whole, our data confirm the importance of the timing of migration of GCPs in the MB pathogenesis and demonstrate, for the first time, the possibility to prevent or fully inhibit MB development by the migration-promoting action of Cxcl3. This chemokine, mimicking the morphogenetic migration process of GCPs from EGL to IGL, forces the pGCPs to differentiate and exit the neoplastic program, instead of controlling their proliferation. Moreover, it is worth mentioning that Cxcl3 is devoid of any intrinsic action on the differentiation or proliferation of the GCPs ([@B3]). Interestingly, a recent report showed that Cxcl3 promotes the proliferation and tumorigenesis of hepatocarcinoma cancer stem cells ([@B28]). This, however, it not surprising, as it is quite common to have cell-specific effects among chemokines, including Cxcl3, and also considering that GCPs, although of epithelial origin as epatic cells, are not stem cells. As an example of different cell specificities, Cxcl3 has different actions on endothelial-derived blood cells, since it promotes the arrest of monocytes ([@B23]), while acts as chemoattractant for neutrophils to areas of brain injury ([@B24]). Thus, different pathways are likely to be involved. In this regard, a recent analysis of genomic pathways in the *Ptch1*^+/-^/*Tis21*^-/-^ mouse model suggests that the chemotaxis mechanism of the GCPs by the Cxcl3-Cxcr2 axis may be clathrin-dependent ([@B6]).

Further studies will be necessary to assess whether Cxcl3 will efficiently reduce the frequency of MBs also starting at later stages of MB development (after 1 month of age). And it will also be necessary to test whether the induction of migration at later stages could be less beneficial because of an increasing refractoriness of the pGCPs to leave the neoplastic program and differentiate, thus increasing the possibility of metastases.

If Cxcl3 will be validated as a therapeutic agent also at later stages of tumorigenesis, this will improve the possibility to use the chemokine in human therapy. Moreover, given that the control of migration of neural precursors is operative also in other neural tumors, this potential therapy may have wider application.
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